Alexander Mayweg

Alexander Mayweg's work experience includes various roles in the pharmaceutical and biotech industry. Alexander started their career at The SEARLE Company Ltd. as a Medicinal Chemistry Placement Research Chemist in 1996. After that, they joined Roche where they held several positions, including Project Leader, Medicinal Chemistry Senior Scientist, and Global Head of Medicinal Chemistry and Principal Leader, VP. Alexander worked for Roche from 2003 to 2016. In 2016, they joined Versant Ventures as an Entrepreneur in Residence and later became a Venture Partner, Partner, and currently serves as a Managing Director. Additionally, they have held board director and leadership positions in various companies such as Black Diamond Therapeutics, Bright Peak Therapeutics, Ridgeline Therapeutics, Monte Rosa Therapeutics, and Enterprise Therapeutics.

Alexander Mayweg completed their Abitur (IB equivalent) at the German School London from 1989 to 1994. Alexander went on to earn a B.Sc. in Chemistry with a Year in Industry from Imperial College London, completing their studies from 1994 to 1998. Following that, Alexander pursued a D.Phil. in Organic Chemistry at the University of Oxford from 1998 to 2001. Alexander further advanced their education by completing a Post Doc in Organic Chemistry at Stanford University from 2001 to 2003.